Drugs / 68Ga-FAP-2286
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05180162 | Dec 2021 → May 2024 | fibrotic liver disease, pulmonary fibrosis | Thomas Hope | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07523607 | Jun 2026 → Jan 2028 expected | breast cancer | Odense University Hospital | Not yet recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT04939610 Background | Jul 2021 → Jun 2026 overdue | cancer | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 68Ga-FAP-2286 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04939610 ↗ |
| Known as | [68Ga]Ga-HKG301 | “Patients were selected by positive [68Ga]Ga-FAP-2286 (68Ga-FAP-2286, also known as [68Ga]Ga-HKG301) PET/CT imaging on all target lesions (SUVmax ≥1.5× SUVmean of mediastinal...” PMID 42223513 ↗ Jun 2026 |
| Modality | Diagnostic / imaging agent | “68Ga-FAP-2286 IV administered as imaging agent for PET scan.” NCT04939610 ↗ |
| Route | Intravenous | “68Ga-FAP-2286 IV administered as imaging agent for PET scan.” NCT04939610 ↗ |
| Target | FAP | “binds to Fibroblast Activation Protein (FAP)” NCT05180162 ↗ |